Skip to main content

Abstract

Approximately 183,000 women are diagnosed with breast cancer each year in the United States. Breast cancer is the leading cancer and the second leading cause of mortality in women. Limitations of mammography with regards to breast cancer detection in women with dense breasts have prompted a considerable interest in FDG-PET for diagnosing breast cancer.

As a whole body technique, PET stages not only axillary and internal mammary nodes but also the whole body for unexpected sites of disease.

The value of FDG-PET for predicting patient outcome has been established.

The role of PET/CT for primary diagnosis and axillary lymph node involvement has not been studied. Most frequently, PET and PET/CT are used to restage breast cancer, identify sites of disease recurrence and to characterize equivocal anatomical “abnormalities”. Finally, treatment monitoring is another important indication for PET or PET/CT.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 39.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 54.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Suggested Reading

  • Wahl RL, Zasadny K, Helvie M, Hutchins GD, Weber B, Cody R. Metabolic monitoring of breast cancer chemohormonotherapy using positron emission tomography: initial evaluation. J Clin Oncol. 1993;11(11):2101–2111.

    PubMed  CAS  Google Scholar 

  • Crippa F, Agresti R, Donne VD, Pascali C, Bogni A, Chiesa C, De Sanctis V, Schiavini M, Decise D, Bombardieri E. The contribution of positron emission tomography (PET) with 18F-fluorodeoxyglucose (FDG) in the preoperative detection of axillary metastases of breast cancer: the experience of the National Cancer Institute of Milan. Tumori. 1997;83(2):542–543.

    PubMed  CAS  Google Scholar 

  • Smith IC, Welch AE, Hutcheon AW, Miller ID, Payne S, Chilcott F, Waikar S, Whitaker T, Ah-See AK, Eremin O, Heys SD, Gilbert FJ, Sharp PF. Positron emission tomography using [18F]-fluorodeoxy-D-glucose to predict the pathologic response of breast cancer to primary chemotherapy. J Clin Oncol. 2000;18(8): 1676–1688.

    PubMed  CAS  Google Scholar 

  • Schelling M, Avril N, Nährig J, Kuhn W, Römer W, Sattler D, Werner M, Dose J, Janicke F, Graeff H, Schwaiger M. Positron emission tomography using [18F] fluorodeoxyglucose for monitoring primary chemotherapy in breast cancer. J Clin Oncol. 2000;18(8): 1689–1695.

    PubMed  CAS  Google Scholar 

  • Mandelson MT, Oestreicher N, Porter PL, White D, Finder CA, Taplin SH, White E. Breast density as a predictor of mammographic detection: comparison of interval-and screen-detected cancers. J Natl Cancer Inst. 2000;92(13):1081–1087.

    Article  PubMed  CAS  Google Scholar 

  • Avril N, Rosé CA, Schelling M, Dose J, Kuhn W, Bense S, Weber W, Ziegler S, Graeff H, Schwaiger M. Breast imaging with fluorine-18 fluorodeoxy glucose: use and limitations. J Clin Oncol. 2000;18(20):3495–3502.

    PubMed  CAS  Google Scholar 

  • Schirrmeister H, Kühn T, Guhlmann A, Santjohanser C, Hörster T, Nussle K, Koretz K, Glatting G, Rieber A, Kreienberg R, Buck AC, Reske SN. Fluorine-18 2-deoxy-2-fluoro-D-glucose PET in the preoperative staging of breast cancer: comparison with the standard staging procedures. Eur J Nucl Med. 2001;28(3):351–358.

    Article  PubMed  CAS  Google Scholar 

  • Yap CS, Seltzer MA, Schiepers C, Gambhir SS, Rao J, Phelps ME, Valk PE, Czernin J. Impact of whole-body 18F-FDG PET on staging and managing patients with breast cancer: the referring physician’s perspective. J Nucl Med. 2001;42(9):1334–1337.

    PubMed  CAS  Google Scholar 

  • Vranjesevic D, Filmont JE, Meta J, Silverman DH, Phelps ME, Rao J, Valk PE, Czernin J. Whole-body 18F-FDG PET and conventional imaging for predicting outcome in previously treated breast cancer patients. J Nucl Med. 2002;43(3):325–329.

    PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Rights and permissions

Reprints and permissions

Copyright information

© 2004 Springer-Verlag Berlin Heidelberg

About this chapter

Cite this chapter

Czernin, J., Dahlbom, M., Ratib, O., Schiepers, C. (2004). Breast Cancer. In: Atlas of PET/CT Imaging in Oncology. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-18517-5_17

Download citation

  • DOI: https://doi.org/10.1007/978-3-642-18517-5_17

  • Publisher Name: Springer, Berlin, Heidelberg

  • Print ISBN: 978-3-642-62141-3

  • Online ISBN: 978-3-642-18517-5

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics